Lymphoma Treatment, New Hope With CART...3.5 unusual performances per month at Yeouido St. Mary's Hospital
Apr 14, 2025
#1. Kim (58, female) was a recurrent diffuse giant B-cell lymphoma and did not respond to existing chemotherapy, but received 'complete remission' after Carty cell therapy. He has been in a stable condition without any signs of recurrence for 10 months after treatment.
#2. Mr. Lee (34, male) was treated with five types of anticancer drugs, including autologous hematopoietic stem cell transplantation, for diffuse giant B-cell lymphoma, but recurred. After receiving Kati cell therapy, he was diagnosed with complete remission after 1 month, and has been maintained for 8 months now. In particular, daily life was impossible before treatment, but now he has recovered to the point where he can return to work and live a normal life.
Catholic University Yeouido St. Mary's Hospital (Hospital Director Yoon Seung-gyu) is making remarkable achievements in the treatment of lymphoma in Korea through CAR-T cell therapy, a state-of-the-art immune cell therapy. Since the introduction of CAR-T (Kimria Carti and Clinical Research Carti) in March last year, a total of 42 people have been injected or injected, and approximately 3.5 cases per month have been performed within 12 months of the introduction. One year after the introduction of CAR-T, these achievements are rare in Korea, and hospitals with more than 3.5 cases per month are also uncommon. With limited access to CAR-T treatment in Korea, this performance is an indicator that Yeouido St. Mary's Hospital is practically leading the domestic treatment environment.
The Catholic University of Korea Yeouido St. Mary's Hospital's lymphoma center has planned CAR-T cell therapy for a total of 42 patients as of the end of February 2025, and completed treatment for 12 of them since the first injection of CAR-T on March 6 last year. As a result of treatment to date, the initial response rate (complete remission and partial remission) is high at about 85%, and the treatment response is maintained for more than 6 months in more than 65%, proving its effectiveness.
The Lymphoma Center at Yeouido St. Mary's Hospital introduced the first innovative method implemented in Korea through a CAR-T treatment model linked to the Good Manufacturing Practice (GMP), a special cell treatment facility at St. Mary's Hospital in Seoul. A very high level of regulatory compliance and expensive facility investment were essential for conventional CAR-T treatment, but Yeouido St. Mary's Hospital effectively overcame these barriers by establishing a new cooperative model.
This model sets a good precedent for other medical institutions to introduce CAR-T treatment quickly and without large-scale facility investment. Through this, it has overcome the institutional and administrative limitations of CAR-T treatment, greatly improved the likelihood of Korean patients receiving timely treatment, and ultimately contributes to improving the medical environment of expanding access to advanced cell therapy.
Unlike traditional chemotherapy, CAR-T cell therapy is a one-time infusion and can expect long-term treatment effects. It uses the patient's own immune system to attack cancer cells, showing a differentiated therapeutic effect from existing anticancer drugs.
However, side effects inherent to cell therapy such as cytokine release syndrome (CRS) and cranial neurotoxicity (ICANS) have been a major challenge in the early treatment process. Yeouido St. Mary's Hospital is maximizing the treatment effect by operating a professional treatment linkage system that effectively manages these CAR-T treatment-related side effects
Professor Young-woo Jeon (Director of Hematology, Lymphoma Center) emphasized that "The Lymphoma Center at Yeouido St. Mary's Hospital is operating in a balanced way by introducing not only commercial CAR-T treatments but also clinical CAR-T treatments.".
He added that "CAR-T cell therapy is an innovative approach differentiated from conventional chemotherapy, and it is a good example of customized precision medicine using the individual patient's immune system.".
Meanwhile, Yeouido St. Mary's Hospital's lymphoma center is leading the introduction and development of the latest optimal treatments, and continues to conduct research to maximize treatment effects and minimize side effects through balanced introduction of commercial and clinical CAR-T treatments.
In addition, we are exploring the applicability of CAR-T cell therapy to blood diseases other than lymphoma, including multiple myeloma and leukemia, and actively seeking additional treatment options. In particular, it plans to continue its leading role in the domestic CAR-T treatment field by actively participating in the development of next-generation treatments to overcome the limitations of current CAR-T treatments.
#2. Mr. Lee (34, male) was treated with five types of anticancer drugs, including autologous hematopoietic stem cell transplantation, for diffuse giant B-cell lymphoma, but recurred. After receiving Kati cell therapy, he was diagnosed with complete remission after 1 month, and has been maintained for 8 months now. In particular, daily life was impossible before treatment, but now he has recovered to the point where he can return to work and live a normal life.
Catholic University Yeouido St. Mary's Hospital (Hospital Director Yoon Seung-gyu) is making remarkable achievements in the treatment of lymphoma in Korea through CAR-T cell therapy, a state-of-the-art immune cell therapy. Since the introduction of CAR-T (Kimria Carti and Clinical Research Carti) in March last year, a total of 42 people have been injected or injected, and approximately 3.5 cases per month have been performed within 12 months of the introduction. One year after the introduction of CAR-T, these achievements are rare in Korea, and hospitals with more than 3.5 cases per month are also uncommon. With limited access to CAR-T treatment in Korea, this performance is an indicator that Yeouido St. Mary's Hospital is practically leading the domestic treatment environment.
The Catholic University of Korea Yeouido St. Mary's Hospital's lymphoma center has planned CAR-T cell therapy for a total of 42 patients as of the end of February 2025, and completed treatment for 12 of them since the first injection of CAR-T on March 6 last year. As a result of treatment to date, the initial response rate (complete remission and partial remission) is high at about 85%, and the treatment response is maintained for more than 6 months in more than 65%, proving its effectiveness.
The Lymphoma Center at Yeouido St. Mary's Hospital introduced the first innovative method implemented in Korea through a CAR-T treatment model linked to the Good Manufacturing Practice (GMP), a special cell treatment facility at St. Mary's Hospital in Seoul. A very high level of regulatory compliance and expensive facility investment were essential for conventional CAR-T treatment, but Yeouido St. Mary's Hospital effectively overcame these barriers by establishing a new cooperative model.
This model sets a good precedent for other medical institutions to introduce CAR-T treatment quickly and without large-scale facility investment. Through this, it has overcome the institutional and administrative limitations of CAR-T treatment, greatly improved the likelihood of Korean patients receiving timely treatment, and ultimately contributes to improving the medical environment of expanding access to advanced cell therapy.
Unlike traditional chemotherapy, CAR-T cell therapy is a one-time infusion and can expect long-term treatment effects. It uses the patient's own immune system to attack cancer cells, showing a differentiated therapeutic effect from existing anticancer drugs.
However, side effects inherent to cell therapy such as cytokine release syndrome (CRS) and cranial neurotoxicity (ICANS) have been a major challenge in the early treatment process. Yeouido St. Mary's Hospital is maximizing the treatment effect by operating a professional treatment linkage system that effectively manages these CAR-T treatment-related side effects
Professor Young-woo Jeon (Director of Hematology, Lymphoma Center) emphasized that "The Lymphoma Center at Yeouido St. Mary's Hospital is operating in a balanced way by introducing not only commercial CAR-T treatments but also clinical CAR-T treatments.".
He added that "CAR-T cell therapy is an innovative approach differentiated from conventional chemotherapy, and it is a good example of customized precision medicine using the individual patient's immune system.".
Meanwhile, Yeouido St. Mary's Hospital's lymphoma center is leading the introduction and development of the latest optimal treatments, and continues to conduct research to maximize treatment effects and minimize side effects through balanced introduction of commercial and clinical CAR-T treatments.
In addition, we are exploring the applicability of CAR-T cell therapy to blood diseases other than lymphoma, including multiple myeloma and leukemia, and actively seeking additional treatment options. In particular, it plans to continue its leading role in the domestic CAR-T treatment field by actively participating in the development of next-generation treatments to overcome the limitations of current CAR-T treatments.
|
This article was translated by Naver AI translator.
